Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Glioblastoma | Review

miR-1908: a microRNA with diverse functions in cancers and non-malignant conditions

Authors: Soudeh Ghafouri-Fard, Tayyebeh Khoshbakht, Bashdar Mahmud Hussen, Mohammad Taheri, Majid Samsami

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

MicroRNAs (miRNAs) are small-sized transcripts with about 22 nucleotide length. They have been shown to influence almost every aspect of cellular functions through regulation of expression of target genes. miR-1908 is a miRNA with diverse roles in human disorders. This miRNA is encoded by MIR1908 gene on chr11:61,815,161–61,815,240, minus strand. Expression assays have confirmed dysregulation of miR-1908 in cancer-derived cell lines in addition to biological samples obtained from patients affected with cancer. In most assessed cell lines, miR-1908 has an oncogenic role. However, this miRNA has been shown to act as a tumor suppressor in chordoma, lung cancer and ovarian cancer. In addition, several lines of evidence have shown involvement of this miRNA in the pathoetiology of bipolar disorder, myocardial infarction, obesity, renal fibrosis, rheumatoid arthritis and scar formation. In the current review, we elucidate the results of diverse studies which evaluated participation of miR-1908 in these conditions.
Literature
1.
Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafouri-Fard S. MicroRNA: a signature for cancer progression. Biomed Pharmacother. 2021;138:111528.CrossRef
2.
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.CrossRef
3.
Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–80.CrossRef
4.
5.
Zhu Y, Wang Q, Xia Y, Xiong X, Weng S, Ni H, et al. Evaluation of MiR-1908-3p as a novel serum biomarker for breast cancer and analysis its oncogenic function and target genes. BMC Cancer. 2020;20(1):1–12.CrossRef
6.
Yu DS, Song XL, Yan C. Oncogenic miRNA-1908 targets HDAC10 and promotes the aggressive phenotype of cervical cancer cell. Kaohsiung J Med Sci. 2021;37(5):402–10.CrossRef
7.
Xia X, Li Y, Wang W, Tang F, Tan J, Sun L, et al. MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway. Mol Cancer. 2015;14(1):1–14.
8.
Chai Z, Fan H, Li Y, Song L, Jin X, Yu J, et al. miR-1908 as a novel prognosis marker of glioma via promoting malignant phenotype and modulating SPRY4/RAF1 axis. Oncol Rep. 2017;38(5):2717–26.CrossRef
9.
Ma Y, Feng J, Xing X, Zhou B, Li S, Zhang W, et al. miR-1908 overexpression inhibits proliferation, changing Akt activity and p53 expression in hypoxic NSCLC cells. Oncol Res. 2016;24(1):9.CrossRef
10.
Ye S-B, Li Z-L, Luo D-H, Huang B-J, Chen Y-S, Zhang X-S, et al. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014;5(14):5439.CrossRef
11.
Kim HR, Shin CH, Lee H, Choi KH, Nam D-H, Ohn T, et al. MicroRNA-1908-5p contributes to the oncogenic function of the splicing factor SRSF3. Oncotarget. 2017;8(5):8342.CrossRef
12.
Yuan H, Gao Y. MicroRNA-1908 is upregulated in human osteosarcoma and regulates cell proliferation and migration by repressing PTEN expression. Oncol Rep. 2015;34(5):2706–14.CrossRef
13.
Yoshida K, Yokoi A, Matsuzaki J, Kato T, Ochiya T, Kajiyama H, et al. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma. Cancer Sci. 2021;112(12):4977.CrossRef
14.
Urabe F, Kosaka N, Sawa Y, Ito K, Kimura T, Egawa S, et al. The miR-1908/SRM regulatory axis contributes to extracellular vesicle secretion in prostate cancer. Cancer Sci. 2020;111(9):3258.CrossRef
15.
Kim Y, Zhang Y, Pang K, Kang H, Park H, Lee Y, et al. Bipolar disorder associated microRNA, miR-1908-5p, regulates the expression of genes functioning in neuronal glutamatergic synapses. Exp Neurobiol. 2016;25(6):296.CrossRef
16.
Chen Y, Li T, Gao Q, Wang L, Cui L. MiR-1908 improves cardiac fibrosis after myocardial infarction by targeting TGF-β1. Eur Rev Med Pharmacol Sci. 2018;22(7):2061–9.PubMed
17.
Yang L, Shi C-M, Chen L, Pang L-X, Xu G-F, Gu N, et al. The biological effects of hsa-miR-1908 in human adipocytes. Mol Biol Rep. 2015;42(5):927–35.CrossRef
18.
Jiang X, Yang L, Pang L, Chen L, Guo X, Ji C, et al. Expression of obesity-related miR-1908 in human adipocytes is regulated by adipokines, free fatty acids and hormones. Mol Med Rep. 2014;10(2):1164–9.CrossRef
19.
Xie F, Li X, Wei C, Gou L, Dang Y, Shan Z. Transfected miR-1908 inhibits renal fibrosis via targeting transforming growth factor beta 1. Chin J Cell Mol Immunol. 2015;31(12):1682–5.
20.
Yao X, Wang Q, Zeng P, Hou L, Yang Y, Lu D, et al. LncRNA HOTTIP from synovial fibroblast-derived exosomes: a novel molecular target for rheumatoid arthritis through the miR-1908–5p/STAT3 axis. Exp Cell Res. 2021;409(2): 112943.CrossRef
21.
Xie C, Shi K, Zhang X, Zhao J, Yu J. MiR-1908 promotes scar formation post-burn wound healing by suppressing Ski-mediated inflammation and fibroblast proliferation. Cell Tissue Res. 2016;366(2):371–80.CrossRef
22.
Long C, Jiang L, Wei F, Ma C, Zhou H, Yang S, et al. Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS ONE. 2013;8(6): e66676.CrossRef
23.
Lian D, Wang Z, Liu N. MicroRNA-1908 is a biomarker for poor prognosis in human osteosarcoma. Eur Rev Med Pharmacol Sci. 2016;20(7):1258–62.PubMed
24.
Teng C, Zheng H. Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer. Oncol Lett. 2017;14(4):4277–81.CrossRef
25.
Kuhlmann JD, Chebouti I, Kimmig R, Buderath P, Reuter M, Puppel S-H, et al. Extracellular vesicle-associated miRNAs in ovarian cancer–design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance. CCLM. 2019;57(7):1053–62.CrossRef
26.
Banach E, Dmitrzak-Weglarz M, Pawlak J, Kapelski P, Szczepankiewicz A, Rajewska-Rager A, et al. Dysregulation of miR-499, miR-708 and miR-1908 during a depression episode in bipolar disorders. Neurosci Lett. 2017;654:117–9.CrossRef
27.
Gui Y, Xu Z, Jin T, Zhang L, Chen L, Hong B, et al. Using extracellular circulating microRNAs to classify the etiological subtypes of ischemic stroke. Transl Stroke Res. 2019;10(4):352–61.CrossRef
28.
Wohlers I, Bertram L, Lill CM. Evidence for a potential role of miR-1908-5p and miR-3614-5p in autoimmune disease risk using integrative bioinformatics. J Autoimmun. 2018;94:83–9.CrossRef
Metadata
Title
miR-1908: a microRNA with diverse functions in cancers and non-malignant conditions
Authors
Soudeh Ghafouri-Fard
Tayyebeh Khoshbakht
Bashdar Mahmud Hussen
Mohammad Taheri
Majid Samsami
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02709-5

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Review

Regulatory function of DNA methylation mediated lncRNAs in gastric cancer

Research

A novel quantitative prognostic model for initially diagnosed non-small cell lung cancer with brain metastases

Review

Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis

Review

Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview

Primary research

Establishment and validation of a novel invasion-related gene signature for predicting the prognosis of ovarian cancer

Primary research

Rcl1 suppresses tumor progression of hepatocellular carcinoma: a comprehensive analysis of bioinformatics and in vitro experiments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits